Biotech buy

摘要

Pharmaceutical giant AstraZeneca of London will spend around US$ 1.26 billion to buy Ardea Biosciences, it announced on 23 April. Ardea is a biotechnology company based in San Diego, California; its main asset is lesinurad, a potential treatment for gout that is in phase III clinical trials. The deal (worth $1 billion once cash held by Ardea is taken into account) is AstraZenecas largest acquisition since it bought MedImmune, of Gaithersburg, Maryland, for $15.6billion in 2007.